Follow-up of primary Sjogren's syndrome patients presenting positive anti-cyclic citrullinated peptides antibody.

Abstract

Anti-cyclic citrullinated peptide antibody (anti-CCP antibody) is very useful for the diagnosis of rheumatoid arthritis (RA) and is associated with articular erosions. The specificity of anti-CCP antibody in the diagnosis of RA has been reported to be about 95 %. Because of its higher specificity in RA, we assessed the clinical features of primary Sjogren's syndrome (pSS) who were positive for anti-CCP antibody. We assessed the clinical features of 405 pSS patients. After 60 (range 7-98) months, 23 (5.6 %) patients previously diagnosed with pSS had progressed to RA. Comparing the anti-CCP positive group with the negative group, laboratory test results for anti-CCP titer and rheumatoid factor positivity with respect to clinical outcome and progression to RA, arthralgia and arthritis were significantly different. Multivariate regression analysis also showed that anti-CCP antibody titer was independently associated with progression to RA. The odds ratio of anti-CCP positivity in terms of progression to RA was 2.5 (95 % CI 1.7-3.7). Testing for anti-CCP antibody in pSS patients with arthritis may allow for the prediction of progression to RA.

• Authors: Yang-Seon Ryu, Sung-Hwan Park, Jennifer Lee, Seung-Ki Kwok, Ji-Hyeon Ju, Ho-Youn Kim, Chan-Hong Jeon
• Journal: Rheumatology international (Rheumatol Int) Vol. 33 Issue 6 Pg. 1443-6 (Jun 2013) ISSN: 1437-160X [Electronic] Germany
• PMID: 23179261 (Publication Type: Journal Article)

Chemical References

• Autoantibodies
• Peptides, Cyclic
• cyclic citrullinated peptide

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Arthritis, Rheumatoid (diagnosis)
• Autoantibodies (blood)
• Cross-Sectional Studies
• Disease Progression
• Female
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Peptides, Cyclic (immunology)
• Retrospective Studies
• Sjogren's Syndrome (complications, immunology)